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a b s t r a c t
Background: Evaluating clinical outcome prior to concurrent chemoradiotherapy remains challenging for oesophageal squamous cell carcinoma (OSCC) as traditional prognostic markers are assessed at the completion of treatment. Herein, we investigated the potential of using sub-region radiomics as a novel tumour biomarker in
predicting overall survival of OSCC patients treated by concurrent chemoradiotherapy.
Methods: Independent patient cohorts from two hospitals were included for training (n = 87) and validation
(n = 46). Radiomics features were extracted from sub-regions clustered from patients' tumour regions using
K-means method. The LASSO regression for ‘Cox’ method was used for feature selection. The survival prediction
model was constructed based on the sub-region radiomics features using the Cox proportional hazards model.
The clinical and biological signiﬁcance of radiomics features were assessed by correlation analysis of clinical characteristics and copy number alterations(CNAs) in the validation dataset.
Findings: The overall survival prediction model combining with seven sub-regional radiomics features was constructed. The C-indexes of the proposed model were 0.729 (0.656–0.801, 95% CI) and 0.705 (0.628–0.782, 95%CI)
in the training and validation cohorts, respectively. The 3-year survival receiver operating characteristic (ROC)
curve showed an area under the ROC curve of 0.811 (0.670–0.952, 95%CI) in training and 0.805 (0.638–0.973,
95%CI) in validation. The correlation analysis showed a signiﬁcant correlation between radiomics features and
CNAs.
Interpretation: The proposed sub-regional radiomics model could predict the overall survival risk for patients
with OSCC treated by deﬁnitive concurrent chemoradiotherapy.
Fund: This work was supported by the Zhejiang Provincial Foundation for Natural Sciences, National Natural Science Foundation of China.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
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Previous studies revealed that biomarkers such as VEGF, cyclin D1,
Ki-67, and squamous cell carcinoma antigen are prognostic for oesophageal squamous cell carcinoma (OSCC) [1]. These biomarkers are all derived from pathological analysis of tumour samples. Yet there remains a
large cohort of OSCC patients who are physiologically unresectable or
refused surgery. However, personalized treatment regimen and its
long-term efﬁcacy signiﬁcantly rely on bio-physiological assessment of
pre-treatment biomarkers. One alternative is through medical imaging
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Research in context
Evidence before this study
Currently, predicting the clinical outcome remains challenging for
oesophageal squamous cell carcinoma (OSCC) patients treated
by concurrent chemoradiotherapy, as traditional prognostic
markers are mainly assessed at the completion of treatment.
Sub-regional radiomics analysis has been conducted with proven
prognostic power for many cancer types. At present, no previous
studies have applied sub-region based radiomics analysis for survival prediction of OSCC.
Added value of this study
In this study involving two medical centres, we performed a subregion cluster within the tumour region on planning CT. A survival
prediction model for OSCC was then constructed based on the
sub-regional radiomics features. The constructed sub-regional
radiomics survival prediction model showed high prognostic
value in both the training cohort and validation cohort.

and uniformity are correlated with SUVmean (entropy: p-value b .001, r
= 0.748 and uniformity: p-value b .001, r = −0.754, Pearson's correlation) and SUVmax (entropy: p-value = .032, r = 0.469 and uniformity:
p-value = .029, r = − 0.476, Pearson's correlation) in the corresponding
18F-FDG PET scans [10]. In other words, texture features from CT scans
alone may be a prognostic indicator of survival prediction in OSCC. Thus
far, OSCC tumour heterogeneity and its quantitative feature analysis has
been carried out for the whole tumour volume, without the consideration
of intra-tumoral variation in different sub-regions [11,12]. Yet subregional radiomics analysis has been conducted with proven prognostic
power for NSCLC [13] and hepatocellular carcinoma [14]. To the best of
our knowledge, no previous studies have applied sub-region based
radiomics analysis for survival prediction of OSCC.
This study aimed to construct and validate a prognostic model for
pre-treatment survival prediction of OSCC patients, based on subregional radiomics analysis of CT scans. To identify the clinical and molecular basis of quantitative imaging characteristics in this study, we
assessed the association of the radiomics features with the clinical factors and copy number alterations (CNAs). We also compared prediction
accuracy of the sub-regional radiomics model with the whole-tumour
radiomics model and conventional clinical factors.

Implications of all the available evidence

2. Methods

The sub-regional radiomics analysis showed potential in predicting
survival of OSCC patients treated by definitive concurrent chemoradiotherapy, which may improve personalized treatment and
achieve a better outcome for OSCC patients.

2.1. Study design

assessment using computed tomography (CT), magnetic resonance (MR)
and positron emission computed tomography (PET), which all play essential roles in cancer diagnosis and tumour heterogeneity analysis
prior to radiotherapy. More speciﬁcally, PET/CT was used to predict survival in oesophageal cancer patients treated with chemoradiotherapy
[2]. However, there has not been a literature consensus in terms of prognosis power in PET/CT. Atsumi et al. suggested the maximum standardized uptake value (SUVmax) as a strong prognostic marker for primary
OSCC [3]. Lindner et al. found that SUVmax only correlates with survival
of OSCC patient in case of primary surgery but not if patients received
neoadjuvant therapy [4]. However, Myslivecek et al. concluded that the
contribution of (18)F-FDG PET/CT cannot be considered as a potential
marker for outcome of chemoradiotherapy [5]. The controversy over
the use of SUVmax from PET/CT has hampered its utility in clinical practice. Meanwhile, efforts have been focusing on radiomics as a potential
solution in providing surrogate information of the tumour microenvironment utilizing quantiﬁcation methods such as texture analysis [6].
Beukinga et al. found that the combination of texture features extracted
from PET and CT can improve the predictive power of tumour response
to neoadjuvant chemoradiotherapy (nCRT) in locally advanced OSCC,
compared to SUVmax alone [7]. Despite strong clinical indication, the
general clinical use of the PET/CT based radiomics features in tumour response prediction is still limited, in part due to the high cost of PET/CT
scans for patients especially in rural areas or developing countries. CT
scans, on the other hand, are more accessible and recent studies have explored features extracted from CT alone. Hou et al. found that CT-based
radiomics features can be used as imaging biomarkers to predict tumour
response to chemoradiotherapy in OSCC patients [8]. Five CT-based
radiomics features were found to discriminate responders from nonresponders (AUCs from 0.686 to 0.727). Ganeshan et al. showed correlation between unenhanced CT textural features (entropy: p-value = .027,
r = 0.512 and uniformity: p-value = .027, r = −0.521, Pearson's correlation) and PET mean standardized uptake value (SUVmean) of nonsmall cell lung cancer (NSCLC) [9]. Ganeshan et al. applied the same
methodology towards oesophageal carcinoma and found that entropy

Fig. 1 depicts the schema of the present study, with the following
steps: Image Acquisition, Volume of Interest Delineation, Sub-region
Clustering, Features Extraction, Feature Selection, Model Construction
and Validation. CT image datasets from two institutions were used for
training an overall survival prediction model and validation, respectively.
More speciﬁcally, tumour volumes were delineated on the CT scans of the
selected OSCC patients, followed by sub-region clustering and radiomics
feature extraction of different sub-regions. Features that showed signiﬁcant correlation with survival were identiﬁed and paired with the corresponding clinical survival outcomes for training and validation using a
machine learning method. A survival prediction model was constructed
based on the training dataset. The model was then tested using the validation dataset by investigating the underlying genomics correlation of
the developed survival prediction model with CNAs and clinical factors.
We further validated the developed model by comparison with wholetumour based radiomics model and conventional clinical factors.
2.2. Patients
Two cohorts of OSCC patients from Hangzhou Cancer Hospital and
the First Afﬁliated Hospital of Wenzhou Medical University were retrospectively identiﬁed and their CT scans were obtained upon Intuitional
Review Board approval from both hospitals. The written informed consent was waived by IRB based on the retrospective nature of this study.
This study was constructed following ethical guidelines of World Medical Association (WMA) Declaration of Helsinki. Inclusion criteria are
I) histological diagnosis of OSCC and staged according to the 2002
(version 6.0) American Joint Committee on Cancer staging system; II)
medically inoperable or refuse to surgery after discussion by the multidisciplinary treatment team; III) Eastern Cooperative Oncology Group
Performance Status (ECOG PS) of ≤2; and IV) no evidence of severe
organ dysfunction. The exclusion criteria are I) early-stage OSCC; II) evidence of distant metastasis at diagnosis; III) prior administration of surgery or chest radiation or chemotherapy; IV) non-treatment related
death; and V) incomplete data on CT images and overall survivals.
All patients received a planning CT scan for treatment planning purpose, followed by radiotherapy treatment with a total dose of 54–60 Gy
given in 27–30 fractions (2.0 Gy per fraction, 5 days per week). Treatment plans involved 3-dimension conformal photon ﬁelds or Intensity
modulated photon ﬁelds. The majority of OSCC patients received
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Fig. 1. Workﬂow in this study.

deﬁnitive concurrent chemoradiotherapy based on cisplatin regimen.
For patients with advanced ages or poor performance status, radiotherapy alone was delivered to these patients.
Paired CT images and overall survival outcomes of a total of 87 patients diagnosed between May 2012 and November 2016 from Hangzhou Cancer Hospital were used as the training cohort. Same dataset
pairs from 46 patients diagnosed between January 2008 and July 2011
from the First Afﬁliated Hospital of Wenzhou Medical University were
used to validate the developed model and to further improve the
model by feeding in genomics information with CNAs. Apart from age
and sex, patients' clinical characteristics including clinical stage, ECOG
PS, and tumour length were collected for both cohorts.
2.3. Image acquisition
The CT images of the training cohort were obtained from the Brilliance Big Bore CT scanner (Philips Electronics, Eindhoven,
Netherlands) in Hangzhou Cancer Hospital. The scanning voltage and

tube currents were 120 kVp and 406 mAs. The slice thickness ranged
from 3 to 5 mm. The CT images in the validation cohort were scanned
from the LightSpeed Pro 16 CT (GE Medical Systems, Milwaukee) in
the First Afﬁliated Hospital of Wenzhou Medical College, with 120 kVp
and 150 mAs. The slice thickness was 3–8 mm.
2.4. Volume of interest (VOI) delineation and sub-region clustering
The contoured gross tumour volume (GTV) in the radiation treatment planning was used as the volume of interest (VOI) in the training
cohort. Because the patients' radiation therapy plans in the validation
cohort were not well preserved, the VOIs in the validation cohort
were depicted by two radiologists all with more than 10 years of experience. The VOI segmentation was performed using open-source software, ITK-SNAP (http://www.itksnap.org/pmwiki/pmwiki.php). The
regions of VOIs in the validation cohort were agreed by both the two radiologists. Air region in the VOI was excluded with a Hounsﬁeld Unit
(HU) threshold of zero. VOIs were divided into sub-regions based on
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the cluster of HU values and local entropy values of CT images. A moving
window with the size of 9 × 9 was used in the calculation of local entropy [13] on each slice of CT images. The K-means method was used
for clustering sub-regions in this study. The Calinski–Harabasz (CH)
value was used as the criterion in selecting the best number of clusters
at the patient population level [15]. The number of clusters from 2 to10
were tested in this study.
2.5. Feature extraction
To compensate for the difference in radiomics features caused by different reconstruction slice thicknesses and pixel sizes [16], the voxel sizes
of all CT images in this study were reconstructed to 1 × 1 × 5 mm3. The
VOIs were normalized to 64 grey levels to compensate for the variation
of CT scanners. For each sub-region, region volume, shape, intensity,
and texture were quantiﬁed as 548 radiomics features using texture analysis and wavelet decomposition method as described in the study of
Vallieres et al. [17]. For comparison purpose, 548 radiomics features
were also extracted from the whole tumour region for each patient. The
radiomics features used in this study were described in Supplementary
I. All sub-regional partitioning and radiomics feature extraction were performed on MATLAB 2015b (The Mathworks, Natick, MA).
2.6. Feature selection and survival prediction model construction
To eliminate the potential volume change effect caused by subregional analysis on radiomics features, the correlation between the tumour volume and radiomics feature value was assessed using the Pearson correlation method, as compared to the whole tumour region.
Radiomics features with a correlation coefﬁcient (CC) of N0.75 were excluded from further study [18]. The redundant features with high internal
association (CC N 0.75) of all sub-regional radiomics features were further
excluded. The least absolute shrinkage and selection operator (LASSO)
for cox algorithm was used to screen features that were highly correlated
with survival outcomes [19]. The LASSO algorithm controls the number of
selected variables by adjusting the parameter, λ. The objective function of
LASSO algorithm is shown in Function 1, where y is truth label, X is the
feature matrix, β is the coefﬁcients of features and λ is the tuning parameter. The LASSO method was designed to minimize the objective function.
The larger the λ is, the smaller the coefﬁcients of features are. Features
with coefﬁcient of larger than zero were selected. To determinate the
best λ in the LASSO algorithm, the 8-fold cross-validation strategy was
used [20]. The λ resulting the least mean difference between the predicted and actual survival in the cross-validations was used to select the
ﬁnal features. A radiomics score was calculated based on the selected
sub-regional radiomics features and corresponding coefﬁcients. The survival prediction model was built based on the radiomics score using the
Cox proportional hazards model and a radiomics nomogram was constructed based on this model for visualization purpose.
1
jjy−Xβjj22 þ λjjβjj1
2

ð1Þ

2.7. Prognostic performance evaluation
The predictive performance of the radiomics score was evaluated in
the training cohort and veriﬁed in the validation cohort using the concordance index (C-index) [21]. The patients were divided into a highrisk group or low-risk group based on the predicted risk using the proposed model. The receiver operation characteristics (ROC) curve was
used to determine the best cut-off risk to stratify patients. The ROC
curves for 1-year survival, 2-year survival, and 3-year survival were
plotted for the two datasets. The Youden index was used to select the
best cut-off value where the sum of sensitivity and speciﬁcity is maximized [22]. The optimal cut-off in the training dataset was used to

stratify patients in the validation dataset. The Kaplan-Meier survival
analysis and Log-rank test were used to compare the differences between the survival curves of the two groups [23].
2.8. Association of sub-regional radiomics features with clinical factors and
copy number alteration
The Spearman rank correlation test was used to assess the correlation of sub-regional radiomics features included in the survival model
with clinical factors and CNAs in the validation cohort. A corresponding
p-value was used to determine the signiﬁcance of the correlation (pvalue b .05). The CNAs of patients in the validation cohort were acquired
by whole exon sequencing using the Integrated DNA Technologies (IDT)
xGen Exome Research Panel kit for exon capture and sequencing by the
Illumina HiSeq 2500. The alignment was performed by bwa 0.7.13 [24].
All CNAs were called by cn.mops [25] package in R language. A total of
1046 CNAs Indexes were analysed. The speciﬁc CNAs locations of each
CNA index were summarized in the supplementary (Supplementary
Table S3).
2.9. Comparison with whole-tumour based radiomics model
The same workﬂow of feature selection and model construction
were applied in building the whole-tumour survival prediction model
(WTPM) using the training cohort. Its prediction performance was compared with the sub-regional prediction model (SRPM) using the C-index
in both training and validation cohorts.
2.10. Comparison with the clinical factors
The prediction performance of SRPM was also compared with conventional prognostic factors, clinical stage and ECOG PS using the Cindex in both training and validation cohorts.
2.11. Statistical analysis
Statistical analysis was done with the R software (R Core Team. R: A
language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. URL: http://www.R-project.org,
2016). The Mann–Whitney U test and chis-q test were used to compare
the difference in patient clinical characteristics in the two cohorts. The
student t-test was used to compare the C-index of different methods.
3. Results
3.1. Patient characteristics
Patient characteristics in the two cohorts showed consistent demographic distributions, which was summarized in Table 1. The survival
analysis showed no signiﬁcant difference (p-value = .388, Log-rank
test) in survival between the two cohorts (Supplementary Fig. S3).
Among them, 61 and 37 patients were conﬁrmed deceased during the
follow-up period in the training group (70.11%), and the validation
group (80.43%), respectively. The median and mean survival time of
the training cohort were 13.00 months (10.00–19.00, 95% Conﬁdence
Interval [CI]) and 25.66 months (19.85–31.47, 95% CI), respectively. In
the validation cohort, median and mean survival time were
12.77 months (9.77–15.43, 95% CI) and 24.21 months (21.27–33.16,
95% CI), respectively.
3.2. Sub-region cluster and feature extraction
The selection process of the best number of clusters was shown in
(Supplementary Fig. S4). When the number of clusters is four, the CH
value reached the optimal in the training cohort. Thus, the tumour region was clustered into four sub-regions, as shown in Fig. 2c. Finally,
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3.4. Sub-regional radiomics survival prediction model

Table 1
The patient characteristics in training and validation cohorts.
Characteristic
Age, years
Median (range)
Sex
Male
Female
ECOG PS
0–1
2
T stage
T3
T4
N stage
N0
N1
Differentiation
Well
Fairly
Poorly
Clinical Stage
III
IVa
Treatment modality
RT alone
Chemoradiotherapy
Tumour Length (cm)
≤5
N5

Training Cohort
(n = 87)

Validation Cohort
(n = 46)

64 (45–85)

61.5(48–75)

5

p-value

With the coefﬁcient of each radiomics feature in the LASSO method,
the radiomics score can be formulated as:

.611
.122
59
28

37
9

45
42

26
20

38
49

18
28

 Subregion3 LLL GLCM inf1h
þ 16:158

.826

 Subregion4 GLCM Contrast þ 22:5

 Subregion3 HHH GLCM corrm−0:116

7
18
21
.068
36
10

10
77

5
41

49
38

26
20

þ 16:778

.209
11
35

54
33

 Subregion1 HHL GLSZM SZE−9:539
 Subregion1 HHH GLSZM SZE

.613

17
32
38

 Subregion1 LLL GLCM inf2h−14:175
 Subregiona1 HHL Histogram Uniformity−14:671

.73

30
57

Radiomics Score for SRPM ¼ 5:473

.914

.982

RT: radiation therapy.

548 whole-tumour radiomics features and 2192 sub-regional radiomics
features were extracted from each patient.
3.3. Feature selection result
None of radiomics feature were found to have high correlation (CC N
0.75) with the tumour volume. Three hundred and forty features
remained after the internal correlation exclusion. The best lambda was
set as 0.157851, with log(lambda) = −1.846106, as shown in Fig. 3a.
The feature selection process in the LASSO method was shown in
Fig. 3b and c. Seven sub-regional radiomics features with non-zero coefﬁcient at the best lambda were selected in the LASSO method. The detailed information of the seven sub-regional features was described in
Supplementary Table S1. The corresponding coefﬁcient in LASSO and
the p-value in the multivariable analysis for each selected feature were
summarized in Supplementary Table S2. Four features are from subregion 1, two from sub-region 3, and one from sub-region 4. Features
Subregion1_LLL_GLCM_inf2h, Subregion1_HHL_Histogram_Uniformity,
and Subregion3_LLL_GLCM_inf1h are all independent prognostic factors
in the multivariable analysis. The radiomics score was constructed by
summing the seven features multiplied with their corresponding coefﬁcient in LASSO.

ð2Þ

A constant value 22.5 was added to the formula to make positive
radiomics score values. The radiomics survival prediction model was
constructed based on the radiomics score. The constructed nomogram
was shown in Fig. 5.
The predictive performance of the model was tested in the training
set and validation set. The C-index was 0.729 (0.656–0.801, 95% CI)
and 0.705 (0.628–0.782, 95%CI) in the two cohorts, respectively. Our
evaluation result reﬂected good prognostic value of the developed
model. High C-index value in the validation cohort showed survival prediction feasibility of the model for test cohorts.
As shown in Fig. 4, the 1-year survival ROC curve showed an AUC of
0.800 (0.704–0.896, 95%CI) in the training cohort and 0.794
(0.652–0.936, 95%CI) in the validation cohort. The stratiﬁed high-risk
and low-risk group showed signiﬁcant difference of survival in both
the training (p-value b .001, Log-rank test) and validation (p-value b
.001, Log-rank test), as shown in Supplementary Fig. S5. The 2-year survival ROC curve showed an AUC of 0.821 (0.711–0.931, 95%CI) in training and 0.805 (0.638–0.973, 95%CI) in validation. The stratiﬁed high-risk
and low-risk group showed signiﬁcant difference of survival in both
training (p-value b .001, Log-rank test) and validation (p-value =
.012, Log-rank test). The 3-year survival ROC curve showed an AUC of
0.811 (0.670–0.952, 95%CI) in training and 0.805 (0.638–0.973, 95%CI)
in validation. The stratiﬁed high-risk and low-risk group showed significant difference of survival in both the training cohort (p-value b .001,
Log-rank test) and validation cohort (p-value b .001, Log-rank test). Results showed clinical utility of the developed model in stratifying highrisk patients regarding 1-year survival, 2-year survival and 3-year survival for treatment strategies adjustment.
3.5. Clinical and biological association
The correlation analysis showed that subregion1_HHL_Uniformity
was signiﬁcantly correlated with tumour length (Fig. S6).
Subregion1_HHL_SZE and subregion3_HHH_corrm were signiﬁcantly

Fig. 2. (a) The tumour region in the CT images; (b) The local entropy image. (c) The cluster results.
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Fig. 3. (a) The change of partial likelihood deviance with responding to the change of lambda in the cross-validation process. The green line showed the optimal lambda in the LASSO
method with the least partial likelihood deviance. (b) The change of coefﬁcients of each feature in the LASSO method with responding to the change of lambda. (c) The zoomed view
of the coefﬁcient change. The green line showed the optimal lambda. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)

correlated with ECOG PS. Subregion3_LLL_inf1h was correlated with both
clinical stage and tumour length. Subregion4_Contrast was correlated
with the tumour length and ECOG PS.
One hundred and ninety-ﬁve CNAs showed non-zero variance
among patients. Thirty-one CNAs showed signiﬁcant correlation with
at least one of the selected radiomics features (Fig. S7). The correlation
analysis showed the underlying relationship between clinical factors,
gene expression and radiography characteristics in oesophageal
tumours.
3.6. Comparison with whole-tumour based radiomics model
The WRPM were established by the following radiomics score:

Radiomcis Score for WRPM ¼ −11:680
 WholeRegion LLL GLCM inf1h
þ 0:386
 WholeRegion LLH Histogram Skewness−3:223
 WholeRegion LLH Histogram Uniformity−0:021
 WholeRegion LHH NGTDM Strength−3:984
 WholeRegion HHL GLRLM GLV
þ 0:002
 WholeRegion HHH GLSZM GLV

ð3Þ

The WRPM showed a C-index of 0.704 (0.637–0.770, 95%CI) in the
training cohort and 0.601 (0.531–0.672, 95%CI) in the validation cohort.
The C-index of WRPM was lower than that of SRPM, while the statistical
analysis showed non-signiﬁcant difference between the C-indexes of
WRPM and SRPM (p-value = .754[Training]; p-value = .982[Validation], t-test).
3.7. Comparison with clinical model
The clinical stage showed a C-index of 0.510 (0.364–0.656, 95%CI) in
the training cohort and 0.515 (0.272–0.756, 95%CI) in the validation cohort. The ECOG PS showed a C-index of 0.528 (0.401–0.655, 95%CI) in
the training cohort and 0.578 (0.417–0.740, 95%CI) in the validation cohort. Both clinical stage and ECOG PS showed signiﬁcantly lower Cindex than SRPM in the training cohort (p-value = .006 [clinical
stage]; p-value = .004 [ECOG PS], t-test). In the validation cohort, no
signiﬁcant difference was observed at 95% conﬁdence interval for clinical stage (p-value = .059, t-test) and ECOG PS (p-value = .061, t-test).
When the conﬁdence interval is at 90%，the difference has statistically
signiﬁcance.

4. Discussion
In this study, we performed a sub-region cluster within the tumour
region on planning CT. A survival prediction model for OSCC was then
constructed based on the sub-regional radiomics features. The constructed sub-regional radiomics survival prediction model showed
high prognostic value in both the training cohort (C-index = 0.729
(0.656–0.801, 95% CI)) and validation cohort (C-index = 0.705
(0.628–0.782, 95%CI)). Consistent results on the validation cohort
showed utility of this model in independent datasets. The developed
model can provide powerful prognostic information to clinicians before
radiation therapy and help tailor treatment strategy for patients. For patients with high risk as evaluated by our prediction model the outcome
is dismal with chemoradiotherapy and chemoradiotherapy in combination with target drug or immunotherapy are suggested as shown in
many clinical trials [26–28].
We also assessed the correlation between sub-regional radiomics
features and CNAs or clinical factors. The sub-regional radiomics features showed potential in reﬂecting gene expression. The SRPM
outperformed the WRPM regarding C-index in both datasets, while
not statistically signiﬁcant. The SRPM showed superior prognostic
value than conventional clinical factors, clinical stage and ECOG PS
and the difference was statistically signiﬁcant at 90% conﬁdence level.
The encouraging prognostic value of CT-based radiomics may shed
light on the pre-radiotherapy tumour evaluation and prognosis of OSCC.
The sub-region cluster performed in this study demonstrated the
importance of the sub-region analysis in reﬂecting tumour heterogeneity of OSCC. This result is consistent with previous studies which suggested the prognostic role of sub-regional heterogeneity [12]. The
correlation with clinical factors and gene expression showed the potential of sub-regional radiomics features in reﬂecting tumour biological
behaviour. Segal et.al found that genomic activity of human liver cancers can be decoded by non-invasive imaging, namely radiomics features [29]. Combinations of 28 imaging traits can reconstruct 78% of
the global gene expression proﬁles, revealing cell proliferation, liver
synthetic function, and patient prognosis. This study showed the potential of radiomics features to reﬂect gene expression. Also, Hugo et.al suggested that radiomic signature, capturing intratumor heterogeneity, is
associated with underlying gene-expression patterns in lung cancer
[30]. In the study of Xia et.al, eight sub-regional CT radiomics features
were signiﬁcantly correlated with prognostic gene modules in hepatocellular carcinoma [14]. In the present study, we found that, in oesophageal cancers, 31CNAs showed signiﬁcant correlation with at least one
of the selected radiomics features, which is consistent with previous
studies. It may be of interest for future studies to combine radiomics
with genomics in the clinical practice and demonstrate the underlying
biological pathway for radiomics [31]. The sub-regional radiomics analysis method may better quantify the tumour sub-region which was
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Fig. 4. ROC curves for 1-year (a), 2-year (b) and 3-year (c) survival prediction using developed radiomics survival prediction model in the training cohort (a1, b1, c1) and validation cohort
(a2, b2, c2).

more correlated with the tumour growth or aggressiveness [12]. A
seven-feature based radiomics score was constructed in this study including six wavelet-based radiomics features showing the importance
of wavelet decomposition in the radiomics analysis. The wavelet features characterized the heterogeneity at multiple spatial scales which
may help quantify the signiﬁcant radiomics features which were prognostic in OSCC [19,32].

For OSCC patients enrolled in the present study, endoscopic ultrasound (EUS) and CT were both used to for staging. EUS combined
with CT has proven to provide excellent sensitivity and speciﬁcity in
the T stage of oesophageal cancer in a series of studies [33,34]. Currently,
the CT-based sub-region radiomics model in this study could apply for
OS prediction in these patients and suggestion for subsequent treatment choices.

Fig. 5. The constructed radiomics nomogram in this study.
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Additionally, we did whole-exome sequencing for part of the biopsy
specimens during our preliminary experiment and the results indicated
that CNAs were the only signiﬁcant predictor for OS in the studied cohort. In literature, Wang et.al demonstrated that other potential biomarkers identiﬁed by whole-exome and whole-genome sequencing
are also signiﬁcantly correlated with EC prognosis [35]. For OSCC patients with high risks identiﬁed in the current study, deﬁnitive concurrent chemoradiotherapy combined with targeted therapy might be a
useful treatment option for these patients. Based on our previous
phase III study, patients in the deﬁnitive concurrent chemoradiotherapy
and Erlotinib (EGFR-TKI) group had a median OS time of 24.9 months
compared to 20.9 months in non-erlotinib group (p-value = .05) [36].
There are also some limitations in this study. This is a retrospective
study, and the validation cohort is of small size. We did not include
other imaging types that normally would be used in clinical practice,
i.e. PET. Due to the lack of more biological information of patients, we
did not further assess the correlation of developed radiomics model
with other biological mechanisms for OSCC. In addition, we did not include superﬁcial oesophageal cancer in our study as it is usually treated
by endoscopic submucosal dissection in routine practice. Our future research is to explore the radio-genomics model and prospectively validate the proposed model. In addition, we will further assess the
tumour change during radiation therapy regarding our developed
radiomics score, thus verify the established model.

5. Conclusion
We developed and validated a sub-regional radiomics survival
prediction model for OSCC patients. The established model showed
high accuracy in improving personalized treatment for OSCC patients.
The sub-regional radiomics analysis showed encouraging potential in
predicting survival of OSCC treated by radiotherapy and needed to be
further conﬁrmed in larger cohorts.
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